Discretionary sale exceeding $1M without 10b5-1 plan designation.
Metric: $4.94M
Market analytics and operational performance indicators
This surface condenses Rocket Lab SEC disclosures into the metrics that matter most for operating leverage: revenue conversion, gross margin shape, cash position, and surfaced risk signals.
The most recent authoritative filing is compared against the prior filing of the same type.
10-Q · Reported 2026-05-07
+$45.2M (+29.1%) QoQ
From 10-Q filing
+1.2pp (+3.2%) QoQ
Cash & equivalents
+ marketable securities = $1,476.8M total liquidity
+$397.5M (+49.2%) QoQ
Like-for-like 10-Q periods only, so annual filings and preliminary 8-K releases do not distort the trend line.
Quarterly sales reported in SEC filings.
Tracks mix, execution, and launch cadence pressure.
Cash and equivalents at period end.
Each row links to the RKLB.FYI brief and the exact SEC filing behind the extracted metrics.
| Source | |||||
|---|---|---|---|---|---|
Q1'26 Filed 2026-05-07 | 10-Q | $200.3M | 38.2% | $1,205.5M | |
FY'25 Filed 2026-02-26 | 10-K | $601.8M | 34.4% | $1,098.8M | |
Q3'25 Filed 2025-11-10 | 10-Q | $155.1M | 37% | $808M | |
Q2'25 Filed 2025-08-07 | 10-Q | $144.5M | 32.1% | $564.1M |
Forward-looking targets stated by Rocket Lab management in SEC disclosures (earnings press releases and 10-Q/10-K management discussion), extracted automatically with the verbatim quote preserved. Every figure is a management projection — not an analyst estimate, not an RKLB.FYI forecast, and not a guarantee of future results.
“Non-GAAP Gross Margins between 39% and 41%.”
“Non-GAAP Operating Expenses between $106 million and $112 million.”
“Stock-based compensation is currently expected to range from $16 million to $18 million in Q1 2026.”
“Revenue between $185 million and $200 million.”
“remains on track to close out the year with 20+ launches.”
“Non-GAAP Gross Margins between 43% and 45%.”
“Non-GAAP Operating Expenses between $107 million and $113 million.”
“Stock-based compensation is currently expected to range from $15 million to $17 million in Q4 2025.”
“Revenue between $170 million and $180 million.”
“GAAP Gross Margins between 35% and 37%.”
“GAAP Operating Expenses between $104 million and $109 million.”
“Stock-based compensation is currently expected to range from $16 million to $17 million in Q3 2025.”
“Revenue between $145 million and $155 million.”
“Non-GAAP Gross Margins between 30% and 32%.”
“Non-GAAP Operating Expenses between $77 million and $79 million.”
“Stock-based compensation is currently expected to range from $16 million to $18 million in Q1 2025.”
“Revenue between $117 million and $123 million.”
“Non-GAAP Gross Margins between 32% and 34%.”
“Non-GAAP Operating Expenses between $75 million and $77 million.”
“Stock-based compensation is currently expected to range from $12 million to $14 million in Q4 2024.”
“Revenue between $125 million and $135 million.”
“Non-GAAP Gross Margins between 30% and 32%.”
“Non-GAAP Operating Expenses between $69 million and $71 million.”
“Stock-based compensation is currently expected to range from $12 million to $14 million in Q3 2024.”
“Launch Services revenue of approximately $21 million.”
“Non-GAAP Gross Margins between 30% and 32%.”
“Non-GAAP Operating Expenses between $62 million and $64 million.”
“Stock-based compensation is currently expected to range from $14 million to $15 million in Q2 2024.”
“Launch Services revenue between $28 million and $29 million.”
“GAAP Gross Margins between 24% and 26%.”
“GAAP Operating Expenses between $73 million and $75 million.”
“Stock-based compensation is currently expected to range from $12 million to $13 million in Q1 2024.”
“Revenue between $92 million and $98 million.”
“Non-GAAP Gross Margins between 28% to 30%.”
“Non-GAAP Operating Expenses between $38 million to $40 million.”
“Stock-based compensation is currently expected to range from $13 million to $14 million in Q3 2023.”
“Revenue between $73 million and $77 million.”
“Non-GAAP Gross Margins between 22% to 24%.”
“Non-GAAP Operating Expenses between $41 million to $43 million.”
“Stock-based compensation is currently expected to range from $14 million to $15 million in Q2 2023.”
“Space Systems revenue of between $37 million to $40 million.”
“GAAP Gross Margins between -5% to -3%.”
“GAAP Operating Expenses between $44 million to $46 million.”
“Stock-based compensation is currently expected to range from $12 million to $13 million in Q1 2023.”
“Revenue between $51 million and $54 million.”
“Non-GAAP Gross Margins between 16% to 18%”
“Non-GAAP Operating Expenses $28 million to $30 million”
“Basic Shares Outstanding 474 million”
“Space Systems revenue of between $34 million to $37 million”
“GAAP Gross Margins between 12% to 15%”
“GAAP Operating Expenses $41 million to $43 million”
“Basic Shares Outstanding 471 million”
“Space Systems revenue of between $37 million to $40 million”
“GAAP Gross Margins between 11% to 13%”
“GAAP Operating Expenses $39 to $41 million”
“Basic Shares Outstanding 464 million”
“Revenue between $51 and $54 million”
“Expect GAAP gross margins of 13%”
“we are currently only planning for two launches in Q4”
“Expect Non-GAAP operating expenses to range between $19 million and $21 million”
“GAAP Net Loss between $24 million and $26 million”
“Expect Q4 revenue to range between $23 million and $25 million. This does not include any contribution from Planetary Space Corporation as the deal has not closed.”
“Expect FY 2021 Revenue of $50 million to $54 million, with an estimated New Zealand COVID-19 shutdown impact of $10 million to $15 million.”
“Expect GAAP gross margins of -221%, significantly impacted by unabsorbed production period costs related to COVID-19 production shutdown in New Zealand and return-to-flight remediations for the July 29, 2021 US Space Force Mission.”
“Expect GAAP Operating Expenses of $41 million to $43 million impacted by stock based compensation expenses related to a one-time catch-up in vesting of performance restricted stock units now deemed 'probable' to be earned as a result of the August 25, 2021 deSPAC.”
“Q3 Adjusted EBITDA loss of $17 million to $20 million, which reflects adjustments for stock-based compensation, depreciation and amortization, FX gains or losses, Interest Expense, Warrant expense, Taxes and other non-recurring items.”
“Expect Q3 Revenue of approximately $4 million to $5 million, which has been impacted by the COVID-19 Level-4 Alert and lockdown in New Zealand after a Delta variant outbreak, resulting in no further launch activity planned in the quarter.”
Use the heatmap first. Then open the evidence list.
2 signals · 2 high severity
4 · 4 · 2026-06-05
Click a cell or chip to filter. Brief opens analysis. Form opens the SEC source.
Showing 8 of 69 · All signals
Discretionary sale exceeding $1M without 10b5-1 plan designation.
Metric: $4.94M
Discretionary sale exceeding $1M.
Metric: $8,964,092
Director Alexander R. Slusky is executing a second sale of 100,000 shares within a single month (following a sale on May 12, 2026).
Officer Arjun Kampani is engaging in regular sales of common stock, with multiple significant transactions recorded in March and May 2026.
Officer Frank Klein has conducted multiple significant sales of common stock over the past three months, including a sale of 44,390 shares on 05/26/2026.
Officer Marvin Bradford Clevenger has engaged in multiple sales within a short period, including 14,622 shares and 927 shares on May 22, 2026, followed by this current proposal.
Executive Arjun Kampani is proposing a sale of 60,900 shares and has completed multiple sales within the last three months.
Officer Arjun Kampani has filed a notice to sell 9,100 shares; he also completed two larger sales in March 2026 totaling over 52,000 shares.
Financial data is extracted automatically from Rocket Lab SEC filings including 10-K, 10-Q, and preliminary 8-K reports. Management guidance rows quote forward-looking statements verbatim and are always labeled as management projections.
Trend charts use quarterly 10-Q data only, keeping annual filings and preliminary releases out of the like-for-like series.
Brief links open the RKLB.FYI analysis. Form links open the SEC filing used as the source record.